Concepts (244)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Multiple Organ Failure | 15 | 2021 | 144 | 3.500 |
Why?
|
| Plasma Exchange | 11 | 2024 | 87 | 2.240 |
Why?
|
| Sepsis | 15 | 2024 | 524 | 2.110 |
Why?
|
| Disseminated Intravascular Coagulation | 6 | 2020 | 68 | 1.610 |
Why?
|
| Thrombocytopenia | 7 | 2020 | 232 | 1.390 |
Why?
|
| ADAM Proteins | 6 | 2023 | 84 | 1.220 |
Why?
|
| von Willebrand Factor | 10 | 2023 | 199 | 1.220 |
Why?
|
| Lymphohistiocytosis, Hemophagocytic | 5 | 2021 | 146 | 0.980 |
Why?
|
| Endotoxemia | 3 | 2024 | 59 | 0.860 |
Why?
|
| Thrombosis | 6 | 2022 | 534 | 0.820 |
Why?
|
| Shock, Septic | 7 | 2020 | 153 | 0.770 |
Why?
|
| Critical Illness | 10 | 2024 | 614 | 0.720 |
Why?
|
| Hemolytic-Uremic Syndrome | 3 | 2020 | 36 | 0.700 |
Why?
|
| Critical Care | 9 | 2021 | 679 | 0.700 |
Why?
|
| Plasmapheresis | 2 | 2012 | 33 | 0.630 |
Why?
|
| Biliary Tract Diseases | 1 | 2018 | 37 | 0.600 |
Why?
|
| ADAMTS13 Protein | 7 | 2023 | 64 | 0.570 |
Why?
|
| Purpura, Thrombotic Thrombocytopenic | 2 | 2015 | 54 | 0.540 |
Why?
|
| Pediatrics | 7 | 2020 | 1191 | 0.540 |
Why?
|
| Hemodynamics | 6 | 2020 | 867 | 0.520 |
Why?
|
| Life Support Systems | 1 | 2015 | 5 | 0.480 |
Why?
|
| Liver Diseases | 1 | 2018 | 385 | 0.450 |
Why?
|
| Whole Blood Coagulation Time | 1 | 2014 | 14 | 0.440 |
Why?
|
| Factor Xa | 1 | 2014 | 17 | 0.440 |
Why?
|
| Partial Thromboplastin Time | 1 | 2014 | 48 | 0.430 |
Why?
|
| Respiration, Artificial | 3 | 2023 | 485 | 0.420 |
Why?
|
| Drug Monitoring | 1 | 2014 | 180 | 0.390 |
Why?
|
| Heparin | 1 | 2014 | 224 | 0.390 |
Why?
|
| Blood Coagulation Disorders | 2 | 2013 | 106 | 0.390 |
Why?
|
| Liver Transplantation | 4 | 2023 | 1099 | 0.370 |
Why?
|
| Extracorporeal Membrane Oxygenation | 3 | 2017 | 621 | 0.360 |
Why?
|
| Polyethylene Glycols | 2 | 2024 | 250 | 0.360 |
Why?
|
| Influenza A Virus, H1N1 Subtype | 1 | 2012 | 184 | 0.350 |
Why?
|
| Peptide Fragments | 1 | 2015 | 818 | 0.350 |
Why?
|
| Coinfection | 1 | 2012 | 181 | 0.350 |
Why?
|
| Intensive Care Units, Pediatric | 6 | 2019 | 483 | 0.330 |
Why?
|
| Infant | 22 | 2023 | 12941 | 0.330 |
Why?
|
| Thrombotic Microangiopathies | 1 | 2011 | 53 | 0.330 |
Why?
|
| Anticoagulants | 2 | 2014 | 595 | 0.330 |
Why?
|
| Child | 26 | 2023 | 25423 | 0.320 |
Why?
|
| Child, Preschool | 20 | 2021 | 14562 | 0.320 |
Why?
|
| Ferritins | 2 | 2021 | 109 | 0.320 |
Why?
|
| Staphylococcus aureus | 1 | 2012 | 476 | 0.310 |
Why?
|
| Guidelines as Topic | 2 | 2020 | 198 | 0.300 |
Why?
|
| Biliary Atresia | 2 | 2023 | 199 | 0.290 |
Why?
|
| Humans | 47 | 2024 | 132393 | 0.290 |
Why?
|
| Acute Kidney Injury | 1 | 2015 | 669 | 0.290 |
Why?
|
| Staphylococcal Infections | 1 | 2012 | 569 | 0.280 |
Why?
|
| Influenza, Human | 1 | 2012 | 683 | 0.250 |
Why?
|
| Cardiomyopathies | 2 | 2023 | 527 | 0.250 |
Why?
|
| Practice Guidelines as Topic | 3 | 2020 | 1324 | 0.250 |
Why?
|
| Citrulline | 2 | 2024 | 114 | 0.240 |
Why?
|
| Hydrolases | 2 | 2024 | 57 | 0.230 |
Why?
|
| Resuscitation | 4 | 2020 | 266 | 0.210 |
Why?
|
| Biomarkers | 5 | 2017 | 3373 | 0.200 |
Why?
|
| Fibrin | 3 | 2022 | 65 | 0.200 |
Why?
|
| Adolescent | 13 | 2021 | 20225 | 0.200 |
Why?
|
| Lipopolysaccharides | 3 | 2024 | 325 | 0.200 |
Why?
|
| Arginine | 2 | 2024 | 349 | 0.190 |
Why?
|
| Platelet Adhesiveness | 2 | 2015 | 41 | 0.190 |
Why?
|
| Male | 20 | 2024 | 64985 | 0.190 |
Why?
|
| ADP-ribosyl Cyclase 1 | 1 | 2021 | 17 | 0.180 |
Why?
|
| Thromboembolism | 1 | 2022 | 91 | 0.180 |
Why?
|
| HLA-DR Antigens | 1 | 2021 | 81 | 0.180 |
Why?
|
| Female | 19 | 2024 | 70660 | 0.180 |
Why?
|
| Membrane Glycoproteins | 2 | 2021 | 431 | 0.180 |
Why?
|
| Disease Models, Animal | 3 | 2024 | 4699 | 0.170 |
Why?
|
| Macrophage Activation Syndrome | 2 | 2017 | 11 | 0.170 |
Why?
|
| Extracorporeal Circulation | 2 | 2018 | 55 | 0.160 |
Why?
|
| Perioperative Care | 1 | 2021 | 212 | 0.160 |
Why?
|
| Liver Cirrhosis | 3 | 2023 | 929 | 0.150 |
Why?
|
| End Stage Liver Disease | 1 | 2021 | 198 | 0.150 |
Why?
|
| Thromboplastin | 2 | 2016 | 19 | 0.150 |
Why?
|
| Tracheostomy | 1 | 2021 | 201 | 0.150 |
Why?
|
| Phenotype | 2 | 2020 | 4491 | 0.150 |
Why?
|
| Lymphocyte Activation | 1 | 2021 | 724 | 0.150 |
Why?
|
| CD8-Positive T-Lymphocytes | 1 | 2021 | 439 | 0.150 |
Why?
|
| Catheterization, Central Venous | 1 | 2019 | 136 | 0.140 |
Why?
|
| Gene Expression Regulation | 1 | 2007 | 2656 | 0.140 |
Why?
|
| Endothelial Cells | 2 | 2023 | 539 | 0.140 |
Why?
|
| Venous Thrombosis | 1 | 2019 | 169 | 0.140 |
Why?
|
| Retrospective Studies | 10 | 2024 | 17174 | 0.140 |
Why?
|
| Patient Care Bundles | 1 | 2017 | 24 | 0.130 |
Why?
|
| Renal Replacement Therapy | 1 | 2018 | 148 | 0.130 |
Why?
|
| Acute-On-Chronic Liver Failure | 1 | 2018 | 80 | 0.130 |
Why?
|
| Cytochrome P-450 Enzyme System | 1 | 2017 | 140 | 0.130 |
Why?
|
| Cause of Death | 1 | 2018 | 496 | 0.130 |
Why?
|
| Recombinant Proteins | 2 | 2021 | 1438 | 0.120 |
Why?
|
| Shiga Toxins | 1 | 2015 | 2 | 0.120 |
Why?
|
| Endothelium | 1 | 2016 | 71 | 0.120 |
Why?
|
| Hemostasis | 1 | 2016 | 70 | 0.120 |
Why?
|
| Complement Inactivating Agents | 1 | 2015 | 12 | 0.120 |
Why?
|
| Organ Dysfunction Scores | 3 | 2020 | 51 | 0.120 |
Why?
|
| Complement System Proteins | 1 | 2015 | 61 | 0.120 |
Why?
|
| Vasoconstrictor Agents | 3 | 2020 | 143 | 0.120 |
Why?
|
| Coronavirus Infections | 1 | 2020 | 388 | 0.120 |
Why?
|
| Pneumonia, Viral | 1 | 2020 | 399 | 0.120 |
Why?
|
| Case-Control Studies | 2 | 2021 | 3605 | 0.120 |
Why?
|
| Disease Progression | 2 | 2018 | 2208 | 0.110 |
Why?
|
| Risk Factors | 4 | 2023 | 10923 | 0.110 |
Why?
|
| Infant, Newborn | 7 | 2021 | 8490 | 0.110 |
Why?
|
| Granulomatous Disease, Chronic | 1 | 2014 | 69 | 0.110 |
Why?
|
| Fluid Therapy | 3 | 2020 | 142 | 0.110 |
Why?
|
| Models, Statistical | 1 | 2016 | 505 | 0.110 |
Why?
|
| Risk Assessment | 3 | 2016 | 3621 | 0.110 |
Why?
|
| Inflammation Mediators | 1 | 2015 | 261 | 0.100 |
Why?
|
| Evidence-Based Medicine | 2 | 2020 | 663 | 0.100 |
Why?
|
| Blood Coagulation Tests | 1 | 2013 | 63 | 0.100 |
Why?
|
| Prognosis | 4 | 2017 | 5029 | 0.100 |
Why?
|
| Medical Audit | 1 | 2012 | 101 | 0.100 |
Why?
|
| Mitochondria | 1 | 2017 | 737 | 0.090 |
Why?
|
| Animals | 9 | 2024 | 36116 | 0.090 |
Why?
|
| Catheterization, Peripheral | 1 | 2013 | 123 | 0.090 |
Why?
|
| Antibodies, Monoclonal, Humanized | 1 | 2015 | 551 | 0.090 |
Why?
|
| Mice, Inbred C57BL | 2 | 2023 | 4728 | 0.090 |
Why?
|
| Protein Binding | 1 | 2015 | 1830 | 0.090 |
Why?
|
| Respiratory Insufficiency | 1 | 2013 | 237 | 0.090 |
Why?
|
| Diagnosis, Differential | 3 | 2021 | 1951 | 0.080 |
Why?
|
| Hemorrhage | 1 | 2013 | 488 | 0.080 |
Why?
|
| Lung Diseases | 1 | 2013 | 393 | 0.080 |
Why?
|
| Survival Rate | 2 | 2019 | 2186 | 0.080 |
Why?
|
| Randomized Controlled Trials as Topic | 2 | 2012 | 1181 | 0.080 |
Why?
|
| Swine | 2 | 2024 | 1221 | 0.080 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2020 | 3443 | 0.080 |
Why?
|
| Platelet Glycoprotein GPIIb-IIIa Complex | 1 | 2008 | 63 | 0.070 |
Why?
|
| Severity of Illness Index | 2 | 2017 | 3032 | 0.070 |
Why?
|
| Societies, Medical | 1 | 2012 | 745 | 0.070 |
Why?
|
| United States | 5 | 2017 | 11465 | 0.070 |
Why?
|
| Cell Adhesion | 1 | 2008 | 365 | 0.070 |
Why?
|
| Statistics, Nonparametric | 1 | 2008 | 454 | 0.070 |
Why?
|
| Glutathione | 1 | 2008 | 202 | 0.070 |
Why?
|
| Heart Defects, Congenital | 1 | 2019 | 1872 | 0.070 |
Why?
|
| Reference Values | 1 | 2008 | 746 | 0.070 |
Why?
|
| Plasminogen Activator Inhibitor 1 | 1 | 2007 | 50 | 0.070 |
Why?
|
| Analysis of Variance | 1 | 2008 | 1046 | 0.060 |
Why?
|
| Consensus | 2 | 2020 | 714 | 0.060 |
Why?
|
| Mice | 3 | 2023 | 18709 | 0.060 |
Why?
|
| Interferon-gamma | 2 | 2021 | 538 | 0.060 |
Why?
|
| Protein C | 1 | 2006 | 21 | 0.060 |
Why?
|
| Child Mortality | 1 | 2005 | 25 | 0.060 |
Why?
|
| Platelet Count | 2 | 2016 | 141 | 0.060 |
Why?
|
| Patient Transfer | 1 | 2005 | 111 | 0.060 |
Why?
|
| Interleukin-6 | 1 | 2007 | 450 | 0.060 |
Why?
|
| Infant Mortality | 1 | 2005 | 180 | 0.060 |
Why?
|
| Inflammation | 2 | 2024 | 1584 | 0.060 |
Why?
|
| Pandemics | 2 | 2024 | 1187 | 0.060 |
Why?
|
| Medical Order Entry Systems | 1 | 2005 | 113 | 0.060 |
Why?
|
| Acute Disease | 1 | 2007 | 1174 | 0.050 |
Why?
|
| Logistic Models | 1 | 2008 | 1896 | 0.050 |
Why?
|
| Propofol | 1 | 2003 | 48 | 0.050 |
Why?
|
| Treatment Outcome | 3 | 2021 | 12861 | 0.050 |
Why?
|
| Hospital Mortality | 3 | 2017 | 1056 | 0.050 |
Why?
|
| Syndrome | 1 | 2006 | 1146 | 0.050 |
Why?
|
| Combined Modality Therapy | 2 | 2018 | 1314 | 0.050 |
Why?
|
| Hypnotics and Sedatives | 1 | 2003 | 137 | 0.050 |
Why?
|
| GTP-Binding Proteins | 1 | 2023 | 188 | 0.050 |
Why?
|
| Time Factors | 3 | 2019 | 6519 | 0.050 |
Why?
|
| Fibrinolysis | 1 | 2022 | 42 | 0.050 |
Why?
|
| Age Factors | 1 | 2008 | 2960 | 0.050 |
Why?
|
| Predictive Value of Tests | 1 | 2007 | 2280 | 0.040 |
Why?
|
| Biological Availability | 1 | 2021 | 152 | 0.040 |
Why?
|
| Bile Acids and Salts | 1 | 2023 | 257 | 0.040 |
Why?
|
| Oxidoreductases | 1 | 2021 | 101 | 0.040 |
Why?
|
| Human Umbilical Vein Endothelial Cells | 1 | 2021 | 107 | 0.040 |
Why?
|
| Fibrinogen | 2 | 2013 | 163 | 0.040 |
Why?
|
| Systemic Inflammatory Response Syndrome | 1 | 2021 | 174 | 0.040 |
Why?
|
| Tissue Distribution | 1 | 2021 | 404 | 0.040 |
Why?
|
| Algorithms | 2 | 2020 | 1721 | 0.040 |
Why?
|
| Adult | 3 | 2024 | 31578 | 0.040 |
Why?
|
| Proteome | 1 | 2021 | 279 | 0.040 |
Why?
|
| Lactic Acid | 1 | 2020 | 166 | 0.040 |
Why?
|
| Attitude to Health | 1 | 2020 | 261 | 0.040 |
Why?
|
| Follow-Up Studies | 1 | 2008 | 5439 | 0.040 |
Why?
|
| Kinetics | 1 | 2021 | 1349 | 0.040 |
Why?
|
| Central Venous Catheters | 1 | 2019 | 43 | 0.040 |
Why?
|
| Preoperative Period | 1 | 2018 | 97 | 0.040 |
Why?
|
| Cytokines | 1 | 2024 | 1395 | 0.040 |
Why?
|
| Survival Analysis | 1 | 2021 | 1593 | 0.040 |
Why?
|
| Anti-Infective Agents | 1 | 2020 | 269 | 0.030 |
Why?
|
| Chemokine CCL3 | 1 | 2016 | 16 | 0.030 |
Why?
|
| Prospective Studies | 2 | 2019 | 6561 | 0.030 |
Why?
|
| Cardiopulmonary Bypass | 1 | 2019 | 356 | 0.030 |
Why?
|
| Matrix Metalloproteinase 8 | 1 | 2016 | 15 | 0.030 |
Why?
|
| Betacoronavirus | 1 | 2020 | 309 | 0.030 |
Why?
|
| Granzymes | 1 | 2016 | 47 | 0.030 |
Why?
|
| HSP70 Heat-Shock Proteins | 1 | 2016 | 78 | 0.030 |
Why?
|
| Cardiovascular Agents | 1 | 2017 | 90 | 0.030 |
Why?
|
| Glycocalyx | 1 | 2016 | 4 | 0.030 |
Why?
|
| Young Adult | 2 | 2021 | 9728 | 0.030 |
Why?
|
| Interleukin-8 | 1 | 2016 | 220 | 0.030 |
Why?
|
| Research Design | 1 | 2020 | 756 | 0.030 |
Why?
|
| Organ Specificity | 1 | 2016 | 441 | 0.030 |
Why?
|
| NADPH Oxidase 2 | 1 | 2014 | 41 | 0.030 |
Why?
|
| beta-Glucans | 1 | 2014 | 20 | 0.030 |
Why?
|
| Fungemia | 1 | 2014 | 22 | 0.030 |
Why?
|
| Monitoring, Physiologic | 1 | 2017 | 387 | 0.030 |
Why?
|
| Granulocytes | 1 | 2014 | 70 | 0.030 |
Why?
|
| Proteoglycans | 1 | 2014 | 92 | 0.030 |
Why?
|
| Fever of Unknown Origin | 1 | 2014 | 45 | 0.030 |
Why?
|
| Anesthesia | 1 | 2017 | 213 | 0.030 |
Why?
|
| Immunization, Passive | 1 | 2014 | 126 | 0.030 |
Why?
|
| Opportunistic Infections | 1 | 2014 | 79 | 0.030 |
Why?
|
| NADPH Oxidases | 1 | 2014 | 115 | 0.030 |
Why?
|
| Down-Regulation | 1 | 2016 | 714 | 0.030 |
Why?
|
| Catheter Obstruction | 1 | 2013 | 7 | 0.030 |
Why?
|
| Prothrombin Time | 1 | 2013 | 36 | 0.030 |
Why?
|
| Fibrin Fibrinogen Degradation Products | 1 | 2013 | 38 | 0.030 |
Why?
|
| Length of Stay | 1 | 2019 | 1355 | 0.030 |
Why?
|
| Echocardiography | 1 | 2019 | 1099 | 0.030 |
Why?
|
| Up-Regulation | 1 | 2016 | 906 | 0.030 |
Why?
|
| Autopsy | 1 | 2013 | 116 | 0.030 |
Why?
|
| Cross-Sectional Studies | 1 | 2022 | 3681 | 0.030 |
Why?
|
| Nitric Oxide | 1 | 2016 | 491 | 0.020 |
Why?
|
| Precision Medicine | 1 | 2016 | 354 | 0.020 |
Why?
|
| DNA Mutational Analysis | 1 | 2014 | 837 | 0.020 |
Why?
|
| Area Under Curve | 1 | 2013 | 330 | 0.020 |
Why?
|
| ROC Curve | 1 | 2013 | 602 | 0.020 |
Why?
|
| Incidence | 1 | 2019 | 3349 | 0.020 |
Why?
|
| Immunosuppressive Agents | 1 | 2014 | 675 | 0.020 |
Why?
|
| Protein Multimerization | 1 | 2010 | 141 | 0.020 |
Why?
|
| Cohort Studies | 1 | 2019 | 5166 | 0.020 |
Why?
|
| Intensive Care Units | 1 | 2013 | 532 | 0.020 |
Why?
|
| Antigens, Human Platelet | 1 | 2008 | 6 | 0.020 |
Why?
|
| Glutathione Disulfide | 1 | 2008 | 21 | 0.020 |
Why?
|
| Hemorheology | 1 | 2008 | 26 | 0.020 |
Why?
|
| Integrin beta3 | 1 | 2008 | 28 | 0.020 |
Why?
|
| Cricetulus | 1 | 2008 | 96 | 0.020 |
Why?
|
| CHO Cells | 1 | 2008 | 166 | 0.020 |
Why?
|
| Pulsatile Flow | 1 | 2008 | 128 | 0.020 |
Why?
|
| Cricetinae | 1 | 2008 | 398 | 0.020 |
Why?
|
| Stress, Mechanical | 1 | 2008 | 176 | 0.020 |
Why?
|
| Anti-Bacterial Agents | 1 | 2020 | 2502 | 0.020 |
Why?
|
| Sensitivity and Specificity | 1 | 2013 | 2141 | 0.020 |
Why?
|
| Oxidation-Reduction | 1 | 2008 | 463 | 0.020 |
Why?
|
| Protein Isoforms | 1 | 2008 | 426 | 0.020 |
Why?
|
| Umbilical Veins | 1 | 2007 | 73 | 0.020 |
Why?
|
| Microcirculation | 1 | 2007 | 112 | 0.020 |
Why?
|
| Transfection | 1 | 2008 | 1090 | 0.020 |
Why?
|
| In Vitro Techniques | 1 | 2007 | 992 | 0.020 |
Why?
|
| Endothelium, Vascular | 1 | 2007 | 508 | 0.010 |
Why?
|
| Contraindications | 1 | 2003 | 81 | 0.010 |
Why?
|
| United States Food and Drug Administration | 1 | 2003 | 158 | 0.010 |
Why?
|
| Safety | 1 | 2003 | 223 | 0.010 |
Why?
|
| Fatty Acids | 1 | 2003 | 369 | 0.010 |
Why?
|